JP2007505033A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007505033A5 JP2007505033A5 JP2006519734A JP2006519734A JP2007505033A5 JP 2007505033 A5 JP2007505033 A5 JP 2007505033A5 JP 2006519734 A JP2006519734 A JP 2006519734A JP 2006519734 A JP2006519734 A JP 2006519734A JP 2007505033 A5 JP2007505033 A5 JP 2007505033A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition
- amino acid
- acid sequence
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 56
- 230000002163 immunogen Effects 0.000 claims 25
- 108091006027 G proteins Proteins 0.000 claims 23
- 102000030782 GTP binding Human genes 0.000 claims 23
- 108091000058 GTP-Binding Proteins 0.000 claims 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims 19
- 230000002209 hydrophobic effect Effects 0.000 claims 17
- 108020001507 fusion proteins Proteins 0.000 claims 13
- 102000037865 fusion proteins Human genes 0.000 claims 13
- 230000004044 response Effects 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 8
- 230000002134 immunopathologic effect Effects 0.000 claims 8
- 241000725643 Respiratory syncytial virus Species 0.000 claims 7
- 230000028993 immune response Effects 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
- 239000002671 adjuvant Substances 0.000 claims 4
- 210000004899 c-terminal region Anatomy 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 230000001681 protective effect Effects 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 3
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 206010014950 Eosinophilia Diseases 0.000 claims 2
- 101710085938 Matrix protein Proteins 0.000 claims 2
- 101710127721 Membrane protein Proteins 0.000 claims 2
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims 2
- 102000002933 Thioredoxin Human genes 0.000 claims 2
- 229940037003 alum Drugs 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 229920002704 polyhistidine Polymers 0.000 claims 2
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 claims 2
- 108060008226 thioredoxin Proteins 0.000 claims 2
- 229940094937 thioredoxin Drugs 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 201000009732 pulmonary eosinophilia Diseases 0.000 claims 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48780403P | 2003-07-15 | 2003-07-15 | |
| US56758604P | 2004-05-03 | 2004-05-03 | |
| US10/888,805 US7368537B2 (en) | 2003-07-15 | 2004-07-09 | Subunit vaccine against respiratory syncytial virus infection |
| PCT/CA2004/001007 WO2005007189A1 (en) | 2003-07-15 | 2004-07-14 | Subunit vaccine against respiratory syncytial virus infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007505033A JP2007505033A (ja) | 2007-03-08 |
| JP2007505033A5 true JP2007505033A5 (enExample) | 2007-08-30 |
Family
ID=34084525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006519734A Pending JP2007505033A (ja) | 2003-07-15 | 2004-07-14 | 呼吸器合胞体得ウイルス感染に対するサブユニットワクチン |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7368537B2 (enExample) |
| EP (2) | EP1651264B1 (enExample) |
| JP (1) | JP2007505033A (enExample) |
| AT (1) | ATE451119T1 (enExample) |
| AU (1) | AU2004257363A1 (enExample) |
| CA (1) | CA2532164A1 (enExample) |
| DE (1) | DE602004024542D1 (enExample) |
| ES (1) | ES2337901T3 (enExample) |
| WO (1) | WO2005007189A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE489968T1 (de) * | 2001-03-09 | 2010-12-15 | Id Biomedical Corp Quebec | Proteosom-liposaccharid-vakzine-adjuvans |
| US7255867B2 (en) * | 2002-11-15 | 2007-08-14 | Id Biomedical Corporation Of Quebec | Vaccine |
| US7368537B2 (en) * | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
| EP2174665B1 (en) | 2003-10-22 | 2016-11-16 | ID Biomedical Corporation of Quebec | Compositions and methods for activating innate and allergic immunity |
| EP1761276B1 (en) * | 2004-06-25 | 2013-07-24 | ID Biomedical Corporation of Quebec | Compositions and methods for treating neurological disorders |
| WO2009079796A1 (en) | 2007-12-24 | 2009-07-02 | Id Biomedical Corporation Of Quebec | Recombinant rsv antigens |
| KR20110045008A (ko) * | 2008-07-18 | 2011-05-03 | 아이디 바이오메디컬 코포레이션 오브 퀘벡 | 키메라 호흡기 세포융합 바이러스 폴리펩티드 항원 |
| US20110318376A1 (en) * | 2008-12-24 | 2011-12-29 | University Of Rochester | Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins |
| AU2009348078B2 (en) * | 2009-06-19 | 2013-03-14 | Eyegene Inc. | Vaccine for cervical cancer |
| AU2010264688A1 (en) | 2009-06-24 | 2012-01-19 | Glaxosmithkline Biologicals S.A. | Recombinant RSV antigens |
| WO2010149743A2 (en) | 2009-06-24 | 2010-12-29 | Id Biomedical Corporation Of Quebec | Vaccine |
| US9849173B2 (en) | 2009-07-06 | 2017-12-26 | Variation Biotechnologies Inc. | Methods for preparing vesicles and formulations produced therefrom |
| WO2011005772A1 (en) | 2009-07-06 | 2011-01-13 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
| SI3178490T1 (sl) | 2009-07-15 | 2022-08-31 | Glaxosmithkline Biologicals S.A. | Sestavki proteina F RSV-ja in postopki za pripravo le-teh |
| US8846056B2 (en) * | 2009-08-04 | 2014-09-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control | Anti-RSV immunogens and methods of immunization |
| US20120237536A1 (en) | 2009-09-10 | 2012-09-20 | Novartis | Combination vaccines against respiratory tract diseases |
| US8730396B2 (en) * | 2010-06-23 | 2014-05-20 | MindTree Limited | Capturing events of interest by spatio-temporal video analysis |
| DK3243526T3 (da) | 2010-07-06 | 2020-02-17 | Glaxosmithkline Biologicals Sa | Levering af rna til at udløse flere immunsignalveje |
| JP6119030B2 (ja) | 2010-07-06 | 2017-04-26 | ヴァリエーション バイオテクノロジーズ インコーポレイテッド | インフルエンザを治療するための組成物及び方法 |
| BR112013000244A2 (pt) | 2010-07-06 | 2016-05-17 | Novartis Ag | lipossomas com lipídeos apresentando pka vantajoso para administração de rna |
| EP2591114B1 (en) * | 2010-07-06 | 2016-06-08 | GlaxoSmithKline Biologicals SA | Immunisation of large mammals with low doses of rna |
| PL2590676T3 (pl) * | 2010-07-06 | 2017-02-28 | Glaxosmithkline Biologicals Sa | Wirionopodobne cząstki dostarczające dla autoreplikujących się cząsteczek rna |
| EP2590675B1 (en) | 2010-07-07 | 2018-08-29 | Artificial Cell Technologies, Inc. | Respiratory syncytial virus antigenic compositions and methods |
| RS63315B1 (sr) * | 2010-08-31 | 2022-07-29 | Glaxosmithkline Biologicals Sa | Pegilovani lipozomi za isporuku rnk koja kodira imunogen |
| MX341989B (es) * | 2010-08-31 | 2016-09-09 | Novartis Ag * | Liposomas pequeños para el suministro de arn que codifica el inmunogeno. |
| CA2814386C (en) | 2010-10-11 | 2019-08-20 | Novartis Ag | Antigen delivery platforms |
| KR20120068647A (ko) * | 2010-12-18 | 2012-06-27 | 아이진 주식회사 | 개선된 면역반응을 유도하는 백신 |
| US20130323280A1 (en) * | 2011-01-13 | 2013-12-05 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
| MX359103B (es) | 2011-01-13 | 2018-09-14 | Variation Biotechnologies Inc | Composiciones y sus usos en el tratamiento de infecciones virales. |
| RU2456020C1 (ru) * | 2011-03-30 | 2012-07-20 | Государственное образовательное учреждение дополнительного профессионального образования Российская медицинская академия последипломного образования Федерального агентства по здравоохранению и социальному развитию (ГОУ ДПО РМАПО Росздрава) | Способ профилактики гриппа и острых респираторных инфекций у детей с бронхиальной астмой |
| EA034702B1 (ru) * | 2011-04-26 | 2020-03-10 | Молекулар Экспресс, Инк. | Липосомные композиции |
| SI3275892T1 (sl) | 2011-05-13 | 2020-06-30 | Glaxosmithkline Biologicals S.A. | Prefuzijski RSV F antigeni |
| CA2840989A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| CA2894442C (en) | 2012-01-12 | 2020-01-21 | Variation Biotechnologies Inc. | Compositions and methods for treating viral infections |
| US20150079077A1 (en) | 2012-01-27 | 2015-03-19 | Variation Biotechnologies, Inc. | Methods and compositions for therapeutic agents |
| WO2014019718A1 (en) | 2012-08-01 | 2014-02-06 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine |
| US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
| JP2015525794A (ja) | 2012-08-06 | 2015-09-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法 |
| CA2919773A1 (en) | 2013-08-05 | 2015-02-12 | Glaxosmithkline Biologicals S.A. | Combination immunogenic compositions |
| US9415101B2 (en) * | 2013-09-25 | 2016-08-16 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
| KR101695518B1 (ko) * | 2014-09-30 | 2017-01-12 | 이화여자대학교 산학협력단 | 호흡기 신시치아 바이러스 범용 백신 |
| US10835601B2 (en) | 2015-11-10 | 2020-11-17 | Ohio State Innovation Foundation | Methods and compositions related to accelerated humoral affinity |
| WO2019075400A1 (en) * | 2017-10-13 | 2019-04-18 | Trellis Bioscience, Llc | CONFORMATIONAL EPITOPES IN A CENTRAL PROTECTED REGION OF SYNCYTIAL RESPIRATORY VIRUS PROTEIN G |
| JP2021534239A (ja) | 2018-08-08 | 2021-12-09 | トレリス・バイオサイエンス，エルエルシー | Ｒｓｖの改善された受動的および能動的ワクチン |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4707543A (en) * | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines |
| US5726292A (en) * | 1987-06-23 | 1998-03-10 | Lowell; George H. | Immuno-potentiating systems for preparation of immunogenic materials |
| US5576016A (en) * | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
| US5961970A (en) * | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| DK0854729T3 (da) * | 1995-09-18 | 2004-07-12 | Id Biomedical Corp Quebec | Forbedrede fremgangsmåder til fremstillingen af ikke-kovalent kompleksdannede og multivalente proteosom-subunit-vacciner |
| US5848152A (en) | 1995-09-26 | 1998-12-08 | Motorola, Inc. | Communication device having interchangeable faceplates and active keypad cover |
| ES2236946T3 (es) * | 1997-09-19 | 2005-07-16 | Wyeth Holdings Corporation | Peptidos derivados de la proteina de union (g) del virus respiratorio sincitial. |
| US6699478B1 (en) * | 1997-09-19 | 2004-03-02 | Wyeth Holdings Corporation | Enhanced immune response to attachment (G) protein of Respiratory Syncytial Virus |
| WO2001060402A2 (en) * | 2000-02-15 | 2001-08-23 | Intellivax International Inc. | Proteosome influenza vaccine |
| FR2819810B1 (fr) | 2001-01-23 | 2004-05-28 | Pf Medicament | Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin |
| ATE489968T1 (de) * | 2001-03-09 | 2010-12-15 | Id Biomedical Corp Quebec | Proteosom-liposaccharid-vakzine-adjuvans |
| US7368537B2 (en) * | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
-
2004
- 2004-07-09 US US10/888,805 patent/US7368537B2/en not_active Expired - Fee Related
- 2004-07-14 AT AT04761567T patent/ATE451119T1/de not_active IP Right Cessation
- 2004-07-14 JP JP2006519734A patent/JP2007505033A/ja active Pending
- 2004-07-14 EP EP04761567A patent/EP1651264B1/en not_active Expired - Lifetime
- 2004-07-14 CA CA002532164A patent/CA2532164A1/en not_active Abandoned
- 2004-07-14 DE DE602004024542T patent/DE602004024542D1/de not_active Expired - Lifetime
- 2004-07-14 WO PCT/CA2004/001007 patent/WO2005007189A1/en not_active Ceased
- 2004-07-14 ES ES04761567T patent/ES2337901T3/es not_active Expired - Lifetime
- 2004-07-14 EP EP09178294A patent/EP2204188A1/en not_active Withdrawn
- 2004-07-14 AU AU2004257363A patent/AU2004257363A1/en not_active Abandoned
-
2008
- 2008-03-19 US US12/051,397 patent/US20080226673A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007505033A5 (enExample) | ||
| Aguilar et al. | Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen | |
| Tamura et al. | Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine | |
| JP2012501959A5 (enExample) | ||
| JP2001514857A (ja) | Ｒｎａ呼吸合包体ウイルスワクチン | |
| JP7403733B2 (ja) | インフルエンザｈａスプリットワクチンの製造方法 | |
| EP1015595A1 (en) | Peptides derived from the attachment (g) protein of respiratory syncytial virus | |
| KR100341958B1 (ko) | 백신조성물 | |
| AU2022262841A9 (en) | Compositions and methods for preventing rsv and piv3 infections | |
| US7527798B2 (en) | Composition and method for preventing or treating a virus infection | |
| US7354589B2 (en) | Multiple antigenic agents and methods for using the same | |
| CN101891825A (zh) | 乙肝核心蛋白与结核抗原或抗原片段的重组融合蛋白及用途 | |
| Park et al. | Effect of epitope-CpG-DNA-liposome complex without carriers on vaccination of respiratory syncytial virus infection | |
| WO2019045090A1 (ja) | インフルエンザｈａスプリットワクチンの製造方法 | |
| JP2020050605A (ja) | 粘膜アジュバント | |
| US7740860B2 (en) | Composition and method for preventing or treating a virus infection | |
| Nguyen et al. | Subunit vaccine candidates engineered from the central conserved region of the RSV G protein aimed for parenteral or mucosal delivery | |
| Zhang et al. | Respiratory syncytial virus: immunopathology and control | |
| de Haan et al. | Evaluation of a liposome-supplemented intranasal influenza subunit vaccine in a murine model system: induction of systemic and local mucosal immunity | |
| CA2168885C (en) | Vaccine compositions | |
| 李秀玲 et al. | Development of RSV Vaccines | |
| Niederman | Prevention of community-acquired pneumonia | |
| MX2008005634A (en) | Prime boost vaccine for the protection of equines against equine influenza |